Articles

Dr Andrey Antov believes it's important for patients to participate in clinical trials for a multitude of reasons, as clinical trials can benefit both the patient and the healthcare system as a whole. Read More ›

Educating Oncology Professionals on Genetic and Genomic Testing

By Andrey Antov, PhD, MBA

Video

Videos

Dr Andrey Antov provides an overview of the role of Jackson Laboratory in the field of cancer genetic testing and in the education of nurses and navigators who co-manage patients at high risk or with a diagnosis of cancer. Read More ›

Who Should Consider Genetic Testing?

By Andrey Antov, PhD, MBA

Video

Videos

Dr Andrey Antov identifies situations in which people may want to consider genetic testing. Read More ›

The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

Rx Profiler The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

Despite a high initial response rate to platinum/taxane-based therapy in patients with advanced ovarian cancer, the effectiveness of treatment diminishes over time, and most patients relapse.

An Assessment of PARP Inhibitors in the Treatment of Recurrent Ovarian Cancer

By Penny Daugherty, RN, MS, OCN, ONN-CG

Rx Profiler The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

Ovarian cancer is an avaricious tumor that can extend throughout the entire abdominal cavity. It is one of the most difficult diseases to diagnose and the most lethal gynecologic malignancy, being the fifth leading cause of cancer death in women in the United States.

PARP Inhibitors for Maintenance Therapy in Recurrent Platinum-Sensitive Ovarian Cancer

By Ambar Khan, PharmD, BCOP

Rx Profiler The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

Before the 2014 FDA approval of olaparib for the treatment of recurrent ovarian cancer in patients with germline BRCA mutation and the 2016 FDA approval of bevacizumab in combination with chemotherapy for platinum-resistant ovarian cancer, the last FDA approval in ovarian cancer was in the mid-2000s.

The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

Rx Profiler - The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

Despite a high initial response rate to platinum/taxane-based therapy in patients with advanced ovarian cancer, the effectiveness of treatment diminishes over time, and most patients relapse.

An Assessment of PARP Inhibitors in the Treatment of Recurrent Ovarian Cancer

By Penny Daugherty, RN, MS, OCN, ONN-CG

Rx Profiler - The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

Ovarian cancer is an avaricious tumor that can extend throughout the entire abdominal cavity. It is one of the most difficult diseases to diagnose and the most lethal gynecologic malignancy, being the fifth leading cause of cancer death in women in the United States.

PARP Inhibitors for Maintenance Therapy in Recurrent Platinum-Sensitive Ovarian Cancer

By Ambar Khan, PharmD, BCOP

Rx Profiler - The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

Before the 2014 FDA approval of olaparib for the treatment of recurrent ovarian cancer in patients with germline BRCA mutation and the 2016 FDA approval of bevacizumab in combination with chemotherapy for platinum-resistant ovarian cancer, the last FDA approval in ovarian cancer was in the mid-2000s.